Jci_page_head_homepage_01 Jci_page_head_homepage_02
Maki Nakayama, Joshua N. Beilke, Jean M. Jasinski, Masakazu Kobayashi, Dongmei Miao, Marcella Li, Marilyne G. Coulombe, Edwin Liu, John F. Elliott, Ronald G. Gill, George S. Eisenbarth
Published in Volume 117, Issue 7
J Clin Invest. 2007; 117(7):1835–1843 doi:10.1172/JCI31368
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6
Development of IAAs but not insulitis by immunization with insulin B:9–23 peptide.

(AD) Serum from B16:A-dKO mice immunized with native B16:Y insulin B:9–23 peptide (A), B16:A-dKO mice immunized with altered B16:A insulin B:9–23 peptide (B), wild-type B16:Y NOD mice immunized with native B16:Y insulin B:9–23 peptide (C), and wild-type B16:Y NOD/SCID mice that received splenocytes from insulin B:9–23 peptide–immunized B16:A-dKO mice (D) was incubated with I125-insulin in the presence of tetanus toxin peptide (TT), native B16:Y insulin B:9–23 peptide, B16:A insulin B:9–23 peptide, or human insulin. Each line represents an individual mouse. (E) More than 10 pancreatic islets from each B16:A-dKO mouse immunized with B16:Y insulin B:9–23 peptide (n = 10), B16:A insulin B:9–23 peptide (n = 4), or PBS (n = 10) in CFA were evaluated for lymphocytic infiltration. The y axis represents the mean ± SD of the insulitis score.